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Prostate cancer is the most common cancer among western men, with a significant mortality and 
morbidity reported for advanced metastatic disease. Current understanding of metastatic disease 
is limited due to difficulty of sampling as prostate cancer mainly metastasizes to bone. By analysing 
prostate cancer bone metastases using high density microarrays, we found a common genomic copy 
number loss at 6q16.1–16.2, containing the FBXL4 gene, which was confirmed in larger series of bone 
metastases by fluorescence in situ hybridisation (FISH). Loss of FBXL4 was also detected in primary 
tumours and it was highly associated with prognostic factors including high Gleason score, clinical 
stage, prostate-specific antigen (PSA) and extent of disease, as well as poor patient survival, suggesting 
that FBXL4 loss contributes to prostate cancer progression. We also demonstrated that FBXL4 deletion 
is detectable in circulating tumour cells (CTCs), making it a potential prognostic biomarker by ‘liquid 
biopsy’. In vitro analysis showed that FBXL4 plays a role in regulating the migration and invasion of 
prostate cancer cells. FBXL4 potentially controls cancer metastasis through regulation of ERLEC1 
levels. Therefore, FBXL4 could be a potential novel prostate cancer suppressor gene, which may prevent 
cancer progression and metastasis through controlling cell invasion.
Prostate cancer is the most common cancer and second leading cause of cancer death among Western men1. 
Many prostate cancers are indolent, meaning patients die with, rather than of cancer. It is challenging to differen-
tiate between indolent and life-threatening disease. Many indolent cancers are treated unnecessarily with a signif-
icant reduction in quality of life. However, if untreated, prostate cancer may metastasize, and become incurable2. 
Understanding of the genetic drivers of cancer progression to metastatic disease is critical to improve the survival 
rate of prostate cancer patients.
Unlike other cancers, prostate cancer creates osteoblastic rather than osteolytic bone deposits3, 4, which makes 
it particularly relevant to investigate its mechanisms of bone metastasis. However, little is known of the genetic 
changes associated with prostate cancer bone metastasis, partly due to the difficulty in obtaining samples from 
the bone. Many genome-wide studies examined genetic alterations only in localised disease5–8. The majority of 
microarray and genome-wide sequencing studies of advanced prostate cancer only analysed tissue from primary 
tumours or local lymph nodes rather than from distant metastatic sites9–11. Only a few studies have examined 
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genetic changes in advanced lethal prostate cancer at metastatic sites, which included only a small proportion of 
metastases from the bone12–17.
To identify genomic alterations, in particular genes associated with prostate cancer bone metastasis, we per-
formed microarray analysis of fresh frozen prostate cancer bone metastasis samples and found 6q16.1–16.2, con-
taining FBXL4 gene, as commonly deleted genomic region of bone metastatic prostate cancer. Further study 
revealed that FBXL4 was also deleted in a proportion of early stage prostate cancer cases, which was associ-
ated with poor prognosis and reduced survival. We also detected FBXL4 in circulating tumour cells (CTCs). 
Functional analysis of FBXL4 in prostate cancer cell lines suggested its involvement in cell migration and inva-
sion, potentially through regulation of the levels of Endoplasmic Reticulum Lectin 1 (ERLEC1) protein, a regula-
tor of cellular stress-response and promoter of metastatic cell survival18.
Results
Loss of 6q16 and down-regulation of FBXL4 is commonly found in prostate cancer bone metas-
tases. We initially analysed the genomic alterations in six fresh frozen samples of prostate cancer bone metas-
tases by Affymetrix single nucleotide polymorphism (SNP) array 6.0 and found chromosomal copy number 
loss commonly affecting 6q14.1–22.32 with minimum overlapping region at 6q16.1–16.2 in 5/6 cases (Fig. 1a), 
suggesting that this genetic region harbours a potential tumour suppressor gene (TSG). 6q16.1–16.2 contains 
only two genes: a widely expressed FBXL4, a member of the F-box protein family, and BRN2, a master regulator 
of neuronal differentiation and a member of the mammalian class III POU transcription factor family, mainly 
expressed in the developing central nervous system19. 6q16.1–16.2 copy number loss at FBXL4 gene location 
Figure 1. Common loss of 6q16 including FBXL4 locus is present in prostate cancer samples. (a) Minimum 
overlapping region of copy number loss at 6q16.1–16.2 (blue box) in six fresh frozen prostate cancer bone 
metastases detected by Affymetrix SNP array 6.0. Heterozygous deletion is present in all six samples. SNPs with 
normal copy number are depicted in blue, loss in green and gain in red. (b) SNP array results were confirmed 
with copy number analysis of 6q16.1–16.2 at FBXL4 locus by TaqMan DNA copy number assay. Heterozygous 
FBXL4 loss was confirmed in 5/6 samples. Sample 3 (Met 3) with least obvious deletion on SNP array shows 
close to normal FBXL4 copy number by qPCR, indicating a small proportion of cells with this deletion. Error 
bars: SD; n = 3. (c) Representative FISH images of FBXL4 region in prostate clinical samples. FBXL4 copy 
number loss in a metastatic and primary FFPE prostate cancer sample is visible in most nuclei (blue) as a 
reduction in number of red signals (FBXL4) in relation to green (control) signals. Neutral copy number in a 
BPH case is reflected by equal number of red (FBXL4) and green (control) signals per nucleus. Scale bar: 10 µm.
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was confirmed in those samples by TaqMan DNA copy number analysis (Fig. 1b). Additional analysis of FBXL4 
genomic region in a bigger cohort of formalin-fixed, paraffin-embedded (FFPE) prostate cancer bone metastases 
samples by fluorescence in situ hybridisation (FISH) detected loss of this chromosomal region in 11/23 (47.8%) 
cases (Fig. 1c), indicating that FBXL4 gene may be a gene commonly down-regulated in prostate cancer bone 
metastasis. Heterozygous loss of 6q16.1–16.2 also existed in both metastatic PC3 and DU145 prostate cancer cell 
lines, but not in less aggressive 22RV1, LNCaP and VCaP cell lines. We analysed FBXL4 RNA expression levels 
by quantitative reverse transcription polymerase chain reaction (q-RT-PCR) in five bone metastases and four 
primary prostate cancer samples and found a significant reduction in FBXL4 expression in bone metastases and 
primary cancer samples compared to six benign prostatic hyperplasia (BPH) samples (p = 0.001, Kruskal-Wallis 
test, Supplementary Figure 1a). The reduced levels of FBXL4 expression were also present in both cell lines with 
6q16.1–16.2 loss (PC3 and DU145) when compared to cell lines without the loss (22RV1, LNCaP and VCaP cells, 
Supplementary Figure 1b). On the contrary, expression of BRN2, the other gene located within 6q16 deletion, did 
not correlate with cancer progression (p = 0.226, Kruskal-Wallis test) when tested in the same clinical samples 
(Supplementary Figure 1c). All these findings suggest that FBXL4 could be the putative TSG located at the deleted 
region, whose loss may result in prostate cancer progression.
Loss of FBXL4 genomic region is present in primary tumours and correlates with advanced 
prostate cancer disease and prostate cancer specific death. To investigate if loss of FBXL4 genomic 
region also occurs at early stage of prostate cancer development, we analysed 145 primary cancer samples by FISH 
and detected FBXL4 genomic loss in 20 cases (13.8%), but not in any of the 55 BPH cases used as non-neoplastic 
controls (Fig. 1c). The relatively low frequency of FBXL4 genomic region loss in primary tumours and its sig-
nificant increase in frequency in metastatic samples (p = 0.0003, Supplementary Table 1) further supports the 
hypothesis that FBXL4 is a gene that suppresses prostate cancer metastatic progression.
To further elucidate the role of FBXL4 in the natural history of prostate cancer, we investigated FBXL4 copy 
number status in the TransAtlantic Prostate Group (TAPG) cohort of conservatively managed localised pros-
tate adenocarcinomas diagnosed by a transurethral resection of the prostate (TURP) to assess FBXL4 loss as a 
potential cancer prognostic biomarker. FBXL4 loss was present in 77/447 (17%) cases successfully analysed by 
FISH, which is consistent with the above data from a separate cohort of primary prostate cancers. Interestingly, 
FBXL4 loss strongly correlated with high Gleason score and clinical stage (p = 0.0000025 and 0.0005, respectively, 
Table 1) as well as with prostate-specific antigen (PSA) and extent of the disease (p = 0.0002 and 0.00005, respec-
tively). More importantly, loss of FBXL4 was significantly associated with death from prostate cancer (HR 1.7, 
p = 0.009, Fig. 2) by univariate analysis. However, since loss of FBXL4 was strongly correlated with other poor 
Parameter
No FBXL4 
loss FBXL4 loss p value (X2 test)
Gleason score < 7 197 20
0.000003Gleason score = 7 97 22
Gleason score > 7 76 35
Clinical stage T1 104 10
0.0005
Clinical stage T2 83 32
Clinical stage T3 40 16
Clinical stage Tx 63 11
Table 1. Correlation of FBXL4 loss with Gleason scores and clinical stages.
Figure 2. FBXL4 loss is significantly associated with decreased prostate cancer specific survival in univariate 
analysis. Kaplan–Meier survival curves represent conservatively managed localised prostate cancers with or 
without FBXL4 loss. Presence of FBXL4 loss is univariately linked to higher rate of prostate cancer specific death 
(Cox model, HR = 1.738 (1.147–2.633), p = 0.009). Cohort size: 447 cases, with 77 of FBXL4 loss positive.
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prognostic factors such as PSA, as expected, the correlation with patient outcome was not significant in multi-
variate analysis when Gleason score, baseline PSA and extent of the disease were included in the analysis model 
(Supplementary Table 2). Therefore, loss of FBXL4 in prostate cancer tissue, while significantly correlating with 
advanced disease, was not an independent prognostic factor for patient outcome.
As blood samples are more accessible than tissue biopsy for monitoring tumour progression20, we investigated 
whether FBXL4 loss is detectable in prostate cancer circulating tumour cells (CTCs). In six of seven blood samples 
from patients with bone metastatic prostate cancer (Gleason score 4 + 4 or 5 + 5), we detected FBXL4 deletion in 
CTCs (Fig. 3 and Supplementary Table 3). FBXL4 loss was also found in CTCs from a patient with lymph node 
metastasis only, and in a non-metastatic T3 prostate cancer case with high Gleason score 4 + 4. The remaining 
two patients tested had lower Gleason score (3 + 3 and 4 + 3) and no CTCs with FBXL4 loss (Supplementary 
Table 3).
Manipulation of FBXL4 expression level affects cell migration and invasion without affecting 
cell viability. To functionally investigate how FBXL4 contributes to prostate cancer progression, we knocked 
it down with small interfering RNAs (siRNA) in DU145, 22RV1 and PC3 cells (Supplementary Figure 2a). 
Knockdown of FBXL4 had no effect on cell viability (Supplementary Figure 2b) but led to a significant increase 
in cell migration (p = 0.04, 0.02 and 0.002, respectively) for all the three cell lines (Fig. 4a and Supplementary 
Table 4).
We also investigated if FBXL4 affects cell invasion ability. FBXL4 knockdown increased Matrigel invasion in 
all prostate cancer cell lines (p = 0.001, 0.04 and 0.0001 for DU145, 22RV1 and PC3, respectively; Fig. 4b). As 
loss of FBXL4 was found in prostate cancer bone metastases and about 95% of bone organic matter consists of 
collagen, we further analysed cell motility/invasion in the context of a bone microenvironment by seeding pros-
tate cancer cells as a single cell suspension on top of collagen gels. As invading cells produce cellular protrusions 
(pseudopodia) we counted the cells with pseudopodia-like extensions and detected significant motility/invasion 
increase with FBXL4 knockdown compared to cells transfected with non-targeting siRNA in all three cell lines 
tested (p = 0.01, 0.01 and 0.03 for DU145, 22RV1 and PC3 cells respectively, Fig. 4c and Supplementary Table 4). 
These results suggest that FBXL4 knockdown also leads to a modest but consistent increase in cell invasion into 
collagen.
To confirm that FBXL4 expression levels influence cell migration, we used a gene overexpression approach 
to generate HEK293 cells with tetracycline-inducible FBXL4 expression. Gene overexpression was confirmed 
at both RNA and protein levels (Supplementary Figure 3a and b). Overexpression of FBXL4 had no effect on 
cell viability (Fig. 5a), but as expected led to significant (40.4%) reduction in cell migration when compared to 
control cells transfected with an empty vector (p = 0.008, Fig. 5b). As the acquisition of a motile and invading 
phenotype is often linked to the epithelial–mesenchymal transition (EMT) and many F-box proteins are involved 
in regulation of this process21, we investigated the impact of FBXL4 overexpression on the levels of the following 
proteins linked to EMT and cell movement, including mesenchymal markers – vimentin and N-cadherin, epithe-
lial marker CK18, and focal adhesion kinase (FAK). Western Blotting (WB) analysis showed no difference in their 
expression in HEK293 cells overexpressing FBXL4 when compared to control cells (Supplementary Figure 4) 
indicating that FBXL4 may have limited effect on the expression of these proteins.
ERLEC1 is a FBXL4 degradation target. As ERLEC1 protein was previously reported as a binding part-
ner of FBXL422, we investigated the relationship between these two proteins using in vitro FBXL4 overexpres-
sion model. Anti-ERLEC1 antibody specificity was confirmed by western blot in HEK293 cells with ERLEC1 
downregulation (Supplementary Figure 5). Overexpression of FBXL4 in HEK293 cells led to downregulation 
of ERLEC1 protein when compared to control cells without FBXL4 overexpression (Fig. 5c). Overexpression 
of FBXL4 in HEK293 cells led to the reduction in ERLEC1 protein level, suggesting that ERLEC1 is targeted by 
FBXL4 for degradation.
Figure 3. Representative FISH image shows the deletion of FBXL4 in a CTC. CTC and lymphocyte were 
determined by immunofluorescence staining (left four panels). By FISH, two chromosome 1 paracentromere 
(red) regions were detected, but only one FBXL4 (green) was found in the CTC (heterozygous loss), while there 
were two copies of both chromosome 1 paracentromere and FBXL4 regions in the lymphocyte (no copy number 
change). Scale bar: 10 µm.
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Discussion
Bone metastasis is significantly associated with death from prostate cancer and also leads to major and debilitating 
symptoms including ‘bone pain’3, 4. Up to 90% of patients dying from prostate cancer have skeletal metastases23. 
Identifying genetic changes contributing to cancer metastasis to the bone is critical to reduce both prostate cancer 
mortality and morbidity. However, most of the prostate cancer genomic studies have been performed on prosta-
tectomy specimens, including studies of metastatic cancers9–11. Due to the difficulty in obtaining tissue from bone, 
very few cases of metastases from the bone have been included in previous studies12, 13, 15. Identification of driver 
genes for bone metastasis will help the development of biomarkers and therapeutic targets for the palliation and 
possible cure of disease at this site.
By genomic profiling of prostate cancer bone metastatic samples, we found a common genomic deletion at 
6q16.1–16.2 and through further investigations we identified the FBXL4 gene, located within this 6q16.1–16.2 
region, as the putative TSG in regulating prostate cancer bone metastases. The only other gene located within 
the deleted 6q16.1–16.2, BRN2, is a leading regulator of neuronal differentiation, mainly expressed during devel-
opment in cells originated from neural crest. BRN2 is known as an oncogene in melanomas (originating from 
melanocytes derived from neural crest cells)24, neuroendocrine small cell lung cancers (SCLCs)25, where its over-
expression correlates with cell invasiveness and metastatic capacity24, and lethal neuroendocrine prostate can-
cers26. In our clinical samples, only FBXL4 but not BRN2 expression correlated with prostate cancer progression. 
Thus it is unlikely for BRN2 to be a candidate driver gene for this deletion. We also demonstrated that FBXL4 was 
not only commonly deleted in bone metastasis samples but also in early stage cancers, although at significantly 
lower frequency than in the metastatic cancers. The detection of FBXL4 deletion in localised prostate cancer is 
consistent with previous studies, reporting 6q16 deletion as one of the frequent genomic changes27, 28. These find-
ings further support loss of FBXL4 as a driver genetic event in prostate cancer progression to bone metastasis and 
also make the alteration of this gene a potential biomarker to predict prostate cancer progression and outcome.
Consistent with the association of FBXL4 loss with prostate cancer metastasis, we demonstrated that FBXL4 
regulates cell motility and invasiveness by both, FBXL4 knockdown and overexpression. Although the functional 
effect of FBXL4 on migration and invasion of prostate cancer cell lines in our study is low, FBXL4 downregulation 
Figure 4. FBXL4 knockdown leads to increased prostate cancer cell migration and invasion in DU145, 22RV1 
and PC3 cells. (a) Prostate cancer cells transwell migration assay showing increased cell migration with FBXL4 
knockdown. (b) Prostate cancer cell invasion through Matrigel. Exemplary pictures on the right show increased 
number of cells invaded through the Matrigel after FBXL4 knockdown. Invaded cells were formalin-fixed and 
stained with haematoxylin for easy visualisation and counting. (c) Prostate cancer cell migration/invasion on 
collagen. Cells were seeded onto collagen (2 mg/ml) as a single cell suspension and cells with pseudopodia-
like extensions (arrows) were counted as migrating/invading cells52. In all experiments, cells were allowed 
migration/invasion for 24 h. Number of migrating/invading cells was determined by counting the cells in at least 
10 random fields in each of three independent biological experiments. NT, cells transfected with non-targeting 
siRNA; siFBXL4, cells transfected with FBXL4 siRNA; arrows, migrating/invading cells. Error bars show the SDs 
in n = 3 expereiments. p-values were calculated relative to cells transfected with non-targeting siRNA. *p < 0.05, 
**p < 0.01 and ***p < 0.001 (two-tailed Student’s t-test). Scale bar: 50 µm.
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Figure 5. FBXL4 overexpression did not affect cell viability but resulted in reduced HEK293 cell migration 
and ERLEC1 downregulation. (a) 72 h induction of FBXL4 overexpression with 1 µg/ml tetracycline does not 
affect HEK293 cell viability when compared to control HEK293 cells containing empty vector. (b) HEK293 cells 
overexpressing FBXL4 show reduced migration when compared with control HEK293 cells containing empty 
vector. Graph on the left represents average results from three independent experiments. Exemplary pictures on 
the right show reduced number of cells migrated through the transwell membrane after FBXL4 overexpression. 
Migrated cells were formalin-fixed and stained with haematoxylin for easy visualisation and counting. Scale 
bar: 50 µm. (c) Western blots showing that FBXL4 overexpression leads to downregulation of ERLEC1 protein 
levels in HEK293 cells. EV, control cells with empty expression vector; FBXL4, HEK293 cells transfected with 
expression vector containing FBXL4. ‘−‘, no tetracycline treatment; ‘+’, 1 µg/ml tetracycline treatment for 72 h. 
Error bars: SD; n = 3.
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consistently led to the increase while overexpression resulted in the decrease of cell migration and invasiveness. It 
is not unusual that genes with apparent in vivo tumour suppressor or oncogenic capacity have relatively small or 
moderate effect in in vitro assays including a F-box family protein, FBXW7, for its role in cell migration and inva-
sion29–31. It is also known that the effect depends on assay and cell line used32. Therefore, the consistency of our 
results obtained in different cell lines with varied invasiveness, in addition to our clinical sample data, supports 
that FBXL4 regulates prostate cell migration and invasiveness.
FBXL4 is a member of the F-box protein family, which is part of E3 ubiquitin protein ligase complex called the 
SKP1-CUL1-F-box (SCF) complex, involved in protein ubiquitination and degradation33. The exact role of FBXL4 
gene is presently unknown. Apart from the link between rare autosomal recessive FBXL4 loss-of-function and 
splice mutations and early-onset mitochondrial encephalomyopathy34–36, there are no reports on FBXL4 function 
and potential involvement in cancer. However through substrate downregulation, F-box proteins regulate diverse 
biological pathways that control cell growth, division, signalling responses, EMT transition, survival and death37. 
Unsurprisingly, more and more evidence emerges about deregulation of these proteins in human cancer and their 
impact on cancer development, progression and metastasis38, 39. F-box protein family members are known to act 
as oncogenes (e.g. SKP2) or TSG (e.g. FBXW7) often through their ability to control degradation of cell cycle pro-
teins and cell proliferation40 or through induction of EMT29, 41. However, changing FBXL4 expression level did not 
affect cell proliferation or protein levels of EMT markers that we examined, suggesting that FBXL4 may control 
proteins in different cellular pathways, which contribute to prostate cancer invasion and metastasis. Involvement 
of F-box proteins in controlling cancer spread and metastasis is common and can encompass different mecha-
nisms such as resistance to anoikis, a type of detachment-induced apoptosis affecting tumour cells detached from 
primary mass (SKP2 oncogene ref. 42), inhibition of niche formation at distant metastatic site (FBXW7 TSG ref. 
43) or modulates cellular stress response and metastatic potential (FBXW7 TSG ref. 44). Further mechanistic 
investigations are required.
Recent study through proteomics based approach, aiming at the identification of candidate substrates and sta-
bly interacting proteins for a range of F-box family members, discovered several proteins potentially interacting 
with FBXL422. One of them was a luminal resident protein of the endoplasmic reticulum, ERLEC1 and its direct 
interaction with FBXL4 was confirmed by immunoprecipitation/western blot. ERLEC1 is a molecular chaperone 
that plays a role in endoplasmic reticulum stress response45. It is frequently overexpressed in human cancers and 
was identified in lung cancer as a novel cancer invasion and metastasis-related gene controlling the response to 
hypoxia and ER stress18. Ectopic expression of ERLEC1 in lung cancer cells increased their tolerance to hypoxia 
and endoplasmic reticulum stress, protecting the cells from apoptosis, while ERLEC1 knockdown resulted in 
reduction in metastasis in a mouse xenograft model18. In agreement with these findings, we demonstrated that 
overexpression of FBXL4 led to the downregulation of ERLEC1. Thus FBXL4 may prevent cancer metastasis 
through regulation of ERLEC1 protein levels.
The biological role of FBXL4 in suppressing cancer progression to advanced disease was also confirmed by the 
strong associations between FBXL4 loss and high Gleason score, advanced clinical stage, high PSA and large dis-
ease volume in a cohort of conservatively managed localised prostate cancer. The loss of FBXL4 was significantly 
associated with poor patient survival (HR 1.7, p = 0.009) although Gleason score, clinical T stage and serum PSA 
levels were stronger prognostic indicators. Gleason score is a local invasiveness indicator for prostate cancer. The 
strong correlation of FBXL4 loss and Gleason score is consistent with our in vitro observation that FBXL4 is asso-
ciated with cancer cell migration and invasion. Loss of FBXL4 may contribute to cancer cell distribution patterns 
associated with higher Gleason scores and therefore are both associated with bone metastasis and poor prognosis.
We demonstrated that loss of FBXL4 can be detected in prostate cancer CTCs, making it possible to analyse 
FBXL4 status in CTCs to monitor the risk of bone metastasis. CTCs from peripheral blood provide a ‘liquid 
biopsy’, making it possible to frequently and in real time monitor disease progression and response to therapies.
Although mutations in FBXL4 may occur, they are uncommon (https://icgc.org/ and http://cancer.sanger.
ac.uk/) and in a recent exome sequencing study of 150 metastatic castration-resistant prostate cancer, only two 
point mutations were found in FBXL4, while deletion of this genomic region was detected in 20% of samples16. 
Loss of FBXL4 copy number may be the main mechanism that leads to low expression of this gene and resulting 
haplo-insufficiency may contribute to cancer progression. In addition to bone metastasis, 6q16 deletion has been 
commonly observed in prostate cancer metastases to other sites in the body14, 16, 27, 28, making it a more attractive 
biomarker and therapeutic target. Moreover, 6q16 deletion has also been frequently found in other human can-
cers, such as breast, lung, colon, ovarian cancers and malignant melanoma46, where loss of FBXL4 may be a driver 
for cancer progression. Using FBXL4 copy number change as a prognostic marker and targeting the downstream 
pathways of FBXL4 for cancer treatment may have a much broader application than bone metastatic prostate 
cancer. Identification of the proteins which are associated with cell invasion and aggressive disease and whose 
degradation is controlled by FBXL4, such as ERLEC1, has the potential to develop targeted therapies for a large 
number of lethal human cancers with loss of FBXL4.
Materials and Methods
Patient cohort. Six fresh frozen and 43 FFPE prostate cancer bone metastases were collected between 2007–
2012 from The Robert Jones and Agnes Hunt Orthopaedic Hospital in Oswestry, Shropshire. All prostate cancer 
bone metastases came from patients with advanced prostate cancer who were treated for pathological bone frac-
tures. Four fresh frozen primary prostate cancer and four BPH samples as well as FFPE prostate samples, includ-
ing 145 primary tumours and 55 BPH cases, were obtained from Bartshealth NHS Trust in London. Peripheral 
blood samples for CTC isolation were collected from ten prostate cancer patients from Bartshealth NHS Trust, 
London, UK. Tissue microarray sections of FFPE cases of conservatively managed localised prostate adenocar-
cinomas diagnosed by TURP and selected through six UK Cancer Registries (TAPG cohort) were used for prog-
nosis correlation. National approval for TAPG cohort was obtained from the Northern Multi-Research Ethics 
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Committee, followed by local ethics committee approval at each of the collaborating hospital trusts2. The other 
tissue and blood samples were collected and used for this study under ethical approval from the East London 
& the City Research Ethics Committee. Informed written consent was obtained for all tissue samples collected 
prospectively, including all blood samples for CTC analysis. Anonymised retrospectively collected samples were 
obtained from Orchid Tissue Bank (HTA license number: 12199). All tissue samples were reviewed by consultant 
pathologist (Dan Berney) and marked for areas of cancer and BPH. All experiments were carried out in accord-
ance with the approved guidelines.
Cell lines. Five human prostate cancer cell lines, PC-3 (from a bone metastasis), DU-145 (from a brain metas-
tasis), LNCaP (from a lymph node metastasis), VCaP (from a vertebral bone metastasis), and 22RV1 (prostate 
carcinoma), one human osteoblast-like MG63 cell line (osteosarcoma-derived) (ATCC, Manassas, VA, USA) and 
commercial The Tetracycline-Regulated Expression (T-Rex) HEK293 cell line (embryonic kidney cells, which 
stably express the tetracycline (Tet) repressor and are designed for use with the T-REx™ System, Life technology, 
UK) were used in this study and maintained in Dulbecco’s MEM (DMEM) (Sigma Aldrich, UK) containing 10% 
fetal calf serum and 1% penicillin/streptomycin (100 units/ml, Sigma Aldrich, UK). All cell lines were verified 
by microsatellite short tandem repeat (STR) profiling using the ABI AmpF/STR Identifiler kit (Life technology, 
USA).
SNP array analysis. A standard phenol/chloroform method was used to extract DNA from fresh frozen 
bone metastases. Six fresh-frozen prostate cancer bone metastases samples were prepared for hybridisation onto 
Affymetrix SNP 6.0 array chips (Affymetrix, Santa Clara, CA, USA). The samples were processed according to the 
manufacturer’s protocols. All standard quality control steps recommended by manufacturer were also followed in 
the process. Signal intensity data from SNP arrays were analysed using our in-house GOLF (V2.2.10) software47.
FISH analysis. FISH on tissue sections were performed as previously described47. Briefly, FFPE tissue slides 
were de-waxed, rehydrated and boiled in tissue pre-treatment solution for 15 min, followed by 5 min enzyme 
digestion (SPOT-Light Tissue Pre-treatment kit, Invitrogen, Life Technologies, UK). Total of 1 μl of labelled 
probes for each chromosomal locus was mixed with 10 μl of hybridisation buffer and applied on pre-treated 
slides. Slides were then coverslipped, denatured at 95 °C for 10 min, and incubated overnight at 37 °C. Slides 
then underwent standard post-hybridisation washes at 42 °C with 2 × 50% formamide/2x SSC and 2x SSC, 5 min 
each, and were incubated with the streptavidin-Cy3 conjugate (Sigma, UK) followed by anti-DIG-FITC antibody 
(Roche, UK) at 37 °C for 10 min. Eventually, slides were coverslipped with Vectashield antifade containing DAPI 
(Invitrogen, Life Technologies, UK).
For CTCs, cells after immunofluorescence staining were fixed by methanol: acetic acid 3:1 and washed with 
70% acetic acid for 10 min to remove immunofluorescence signals. Bacterial artificial chromosomes (BACs) 
RP11–639P13, CTD-2073H5, RP11–258I9 and CTD-2281M23 were used in combination for FBXL4 region and 
paracentromere of chromosome 1 and 6p12 region (RP11–727H16) were used as controls. The BAC clones were 
obtained from the Institute of Cancer Research (Sutton, UK). BAC DNA labelling was done with BioPrime® 
DNA Labelling System (Invitrogen, Life Technologies, UK) according to the manufacturer protocol. Probes were 
labelled using either biotin-14-dCTP or digoxigenin (DIG)-11-dUTP (Roche, UK).
Both FISH probe signals were counted per nucleus. A minimum of 100 nuclei (cells) with clear hybridisation 
signals were counted per tissue sample and for circulating samples, all countable CTCs were included. The per-
centage of nuclei with less FBXL4 signals than control signals were determined and the widely accepted cutoff 
calculated as the mean of false-positive findings in ten non-malignant controls (BPH samples or lymphocytes 
respectively) plus three times the standard deviation (mean % ± 3 SD) was used for FBXL4 copy number status 
evaluation in each sample48, 49. FISH scoring was done blindly and results given to the statistician who then ana-
lysed them in connection to clinical data.
Quantitative PCR. Total DNA was extracted from cells and tissue using standard phenol-chloroform pro-
tocol. Total RNA was extracted with TRIzol reagent (Invitrogen, Life Technologies, UK) according to manufac-
turer’s instructions. cDNA synthesis was performed with 1 µg of total RNA per sample using Moloney Murine 
Leukemia Virus Reverse Transcriptase, RNase H Minus, Point Mutant kit (Promega, UK). All TaqMan assays 
were performed according to the manufacturer protocols (Life technology, UK). DNA copy number analysis 
of FBXL4 genomic locus was performed with TaqMan DNA copy number assay (Life technology, UK). Copy 
number was analysed with CopyCaller Software v2.0 (Life technology, UK) and normalised to normal male 
DNA. RNase P TaqMan Copy Number Reference Assay was used as endogenous control (Life technology, UK). 
Standard q-RT-PCR was performed using predesigned TaqMan gene expression assays targeting FBXL4 and 
BRN2 (Life technology, UK). The GAPDH gene was used as endogenous control (Life technology, UK).
Gene knockdown by siRNA. Cells plated at a density of 7 × 104 (PC3 and DU145) or 12 × 104 (22RV1) per 
well in six-well plates were transfected with 100 nM of FBXL4-specific smart pool siRNA and control non target-
ing siRNA (GE Dharmacon, Layfayette, CO, USA) using oligofectamine reagent (Life technology, UK) according 
to the manufacturer’s protocols.
FBXL4 overexpression in HEK293 cells. T-REx HEK293 cells were purchased together with a 
tetracycline-regulated mammalian expression system (the T-REx™ system) from Invitrogen, UK. Full-length 
FBXL4 cDNA carrying a 5′-FLAG tag was subcloned into the pcDNA4/TO expression vector and stable pools of 
HEK293 transfectants were generated by selection with 400 µg/ml of zeocin. HEK293 cells transfected with empty 
pcDNA4/TO vector were used as a control. Induction of FBXL4 expression from pcDNA4/TO expression vector 
was done with 1 µg/ml of tetracycline treatment for 48–72 h.
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Western Blotting. Western blotting was performed as previously described50 using anti-FBXL4 (rabbit pol-
yclonal - ab153812, Abcam, UK), anti-ERLEC1 (rabbit polyclonal - ab102046, Abcam, UK), anti-FAK (mouse 
monoclonal - 05–537, Millipore, UK), anti-phospho-FAK (Y397, rabbit monoclonal - ab81298, Abcam, UK), 
anti-N-cadherin (mouse monoclonal - ab98952, Abcam, UK), anti-vimentin (rabbit monoclonal - AC-0024, 
Epitomics, UK) and anti-CK18 (mouse monoclonal - NCL-CK18, Novocastra, UK) antibodies. 30–50 μg of whole 
cell protein lysates in RIPA buffer were mixed with NuPAGE® LDS Sample Buffer (BioRad, UK) and reducing 
agent (BioRad, UK) and denatured at 90 °C for 10 min.
Protein samples were separated on 10% polyacrylamide gels and transferred onto PVDF membranes 
(Millipore, UK). Membranes were next blocked with 5% powder milk in Tris Buffer Saline/0.1% Tween-20 
(TBST) and incubated overnight with primary antibodies, followed by secondary peroxidase conjugated anti-
body (Fisher Scientific, UK) for 1 h at room temperature. Protein detection was done with Immobilon Western 
Chemiluminescent HRP Substrate (Millipore, UK). β actin levels were used as a loading control (mouse mono-
clonal - A5441, Sigma-Aldrich, UK).
CTC isolation and immunofluorescence staining. CTCs were isolated and immunofluorescence stain-
ing was performed on CTC slides as previously described20, 51. Briefly, CTCs from 7.5 ml of peripheral blood sam-
ples from prostate cancer patients were isolated within 1–24 h after blood draw with Parsortix system (ANGLE 
PLC, UK). Parsortix system uses a micro-fluidic cassette to capture and harvest CTCs based on their less deform-
able nature and larger size compared to other blood components. Captured cells were eluted from the cassette 
with 200 µl of buffer and transferred onto a glass slide. Cell solution was then air-dried, followed by 20 min cell 
fixation with 100% acetone on ice.
Immunofluorescence staining was performed using rabbit polyclonal anti-CD45 (Santa Cruz, USA) and 
mouse monocolonal anti-cytokeratin (CK) (Miltenyi Biotec, UK) antibodies. Eventually, CTC slides were 
mounted in SlowFade® gold antifade mountant with DAPI. Stained slides were scanned using Ariol image anal-
ysis system (Leica Microsystems Ltd, Suffolk, UK). A CTC is defined as a nucleated cell with CK+ and CD45−.
Cell viability, migration and invasion assays. Cell viability and proliferation were assessed using the 
CellTiter 96 AQueous Cell Proliferation Assay (MTS) (Promega, UK) following the manufacturer’s instructions. 
3000–5000 cells (depending on cell line) were plated in each well of a 96-well plate. On the following day, pros-
tate cancer cell lines were transfected with anti-FBXL4 siRNA and after 48 h and 72 h, cell viability and prolif-
eration were assessed by MTS assay. T-Rex HEK293 cells were treated with 1 µg/ml tetracycline for 42 h prior 
to MTS assay to ensure FBXL4 overexpression. In vitro transwell migration and Matrigel invasion assays were 
performed by using 24-well, 8-µm pore transwell inserts (Becton Dickinson, UK). 48 h post transfection with 
siRNA, 3 × 104–7 × 104 prostate cancer cells were seeded in 200 µl of serum-free growth medium in the upper 
chamber, and 600 µl of medium with chemo-attractant (10% FCS) was added to the lower chamber. For PC3 
cells, MG63 human osteoblasts cells were used as chemo-attractant. MG63 were seeded at the bottom of 24 
well plate wells and 24 h before experiments old growth medium was removed and replaced with 600 µl of plain 
DMEM. T-Rex HEK293 cells were treated with 1 µg/ml tetracycline for 48 h prior to transwell migration assay to 
ensure FBXL4 overexpression. In all experiments prostate cancer cells were incubated at 37 °C for 24 h, and then 
fixed in 10% buffered formalin and stained with haematoxylin (Fisher Scientific, UK). Cells on the upper surface 
were removed with a cotton swabs, and migrated cells on the underside were counted (average of 10 fields). For 
collagen migration/invasion assay cells 48 h post transfection with FBXL4 and control siRNA were seeded onto 
collagen (2 mg/ml) as a single cell suspension. 24 h later, cells with pseudopodia-like extensions were counted as 
migrating/invading cells52. Number of migrating/invading cells was determined by counting the cells in at least 
10 random fields.
Statistical analysis. Statistical tests included the chi-squared (X2) for FISH data comparison and correlation 
of FBXL4 status with Gleason score and prostate cancer clinical stage, Mann-Whitney U tests for FBXL4 status 
correlation with PSA or extent of disease, Kruskal-Wallis test for q-RT-PCR data and paired Student’s t -test, for 
functional studies. Statistical analyses were performed using the Prism 5.0b (GraphPad, La Jolla, CA, USA) soft-
ware. Values of p < 0.05 were considered significant.
Statistical analysis of TAPG cohort was done with STATA (version 11.2, StataCorp, USA). The primary end 
point was time to death from prostate cancer, assessed with a proportional hazards model. Observations were 
censored on the date of last follow-up, or at death from other causes. For the multivariate Cox proportional haz-
ards models, forward stepwise regression was used. Covariates evaluated were Gleason score, baseline PSA value, 
clinical stage, extent of disease (proportion of positive TURP chips), age at diagnosis and FBXL4 status (FBXL4 
loss versus no loss). All p-values were two-sided and p values of 0.05 or less were considered significant.
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